Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1982 2
1983 1
1984 3
1985 1
1986 3
1987 1
1991 1
1994 1
1995 1
1997 1
1999 1
2000 1
2001 1
2002 2
2004 1
2008 5
2009 8
2010 9
2011 8
2012 5
2013 2
2014 4
2015 3
2016 2
2017 1
2018 1
2019 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Results by year
Filters applied: . Clear all
Page 1
Comparison table: Some lipid-lowering drugs.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Feb 11;61(1565):e24-e30. Med Lett Drugs Ther. 2019. PMID: 30845107 No abstract available.
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP, Keating GM. Yang LP, et al. Am J Cardiovasc Drugs. 2009;9(6):401-9. doi: 10.2165/11203920-000000000-00000. Am J Cardiovasc Drugs. 2009. PMID: 19929038
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. ...Once-daily fenofibric acid 135 mg plus a statin was generally as well tolerated as monotherapy with fenofibric aci
Fenofibric acid activates peroxisome proliferator-activated receptor alpha to modify fatty acid and lipid metabolism. .
Fenofibric Acid (trilipix).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 May 4;51(1311):33-4. Med Lett Drugs Ther. 2009. PMID: 19417718 No abstract available.
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Qiu F, Meng T, Chen Q, Zhou K, Shao Y, Matlock G, Ma X, Wu W, Du Y, Wang X, Deng G, Ma JX, Xu Q. Qiu F, et al. Mol Pharm. 2019 May 6;16(5):1958-1970. doi: 10.1021/acs.molpharmaceut.8b01319. Epub 2019 Mar 26. Mol Pharm. 2019. PMID: 30912953 Free PMC article.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR). However, the effects of fenofibrate through systemic administration are not as potent as desired due to …
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist and has been shown to have therapeutic effects
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH. Roth EM, et al. Am J Cardiovasc Drugs. 2010;10(3):175-86. doi: 10.2165/11533430-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20524719 Clinical Trial.
Primary and secondary variables were mean percent changes in LDL-C comparing rosuvastatin/fenofibric acid 20 mg/135 mg with simvastatin 40 mg and rosuvastatin/fenofibric acid 10 mg/135 mg and rosuvastatin/fenofibric acid 5 mg/135 mg with …
Primary and secondary variables were mean percent changes in LDL-C comparing rosuvastatin/fenofibric acid 20 mg/135 mg with si …
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Jones PH, et al. Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20136164
PATIENTS: Patients with mixed dyslipidemia and type 2 diabetes (n = 586). INTERVENTION: Fenofibric acid (Trilipix) 135 mg monotherapy; low-, moderate-, or high-dose statin monotherapy (rosuvastatin [Crestor] 10, 20, or 40 mg; simvastatin [Zocor] 20, 40, or 80 mg; or …
PATIENTS: Patients with mixed dyslipidemia and type 2 diabetes (n = 586). INTERVENTION: Fenofibric acid (Trilipix) 135 mg mono …
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.
Alagona P Jr. Alagona P Jr. Vasc Health Risk Manag. 2010 May 25;6:351-62. doi: 10.2147/vhrm.s6714. Vasc Health Risk Manag. 2010. PMID: 20531954 Free PMC article. Review.
This review will attempt to provide appropriate background information on lipids/lipoproteins, including non-high density lipoprotein and risk, as well as data available on fibrates and combination pharmacologic therapy. We will review a new agent, TriLipix((R)) (fenofibric
This review will attempt to provide appropriate background information on lipids/lipoproteins, including non-high density lipoprotein and ri …
The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Campbell J, Mohiuddin SM. Campbell J, et al. Drugs Today (Barc). 2010 Oct;46(10):757-64. doi: 10.1358/dot.2010.46.10.1519652. Drugs Today (Barc). 2010. PMID: 21076712 Review.
Diabetes, due to its multifactorial effects, increases the risk of developing cardiovascular disease. ...It does not require first-pass metabolism, but dissociates in the gastrointestinal tract into the pharmacologically active fenofibric acid. This new formu …
Diabetes, due to its multifactorial effects, increases the risk of developing cardiovascular disease. ...It does not require first-pa …
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Wiggins BS, et al. Circulation. 2016 Nov 22;134(21):e468-e495. doi: 10.1161/CIR.0000000000000456. Epub 2016 Oct 17. Circulation. 2016. PMID: 27754879 Review. No abstract available.
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA. Roth EM, et al. Cardiovasc Drugs Ther. 2010 Dec;24(5-6):421-8. doi: 10.1007/s10557-010-6266-4. Cardiovasc Drugs Ther. 2010. PMID: 20953684 Clinical Trial.
This phase 3, multicenter, randomized, double-blind study evaluated the efficacy and safety of rosuvastatin 5 mg coadministered with fenofibric acid 135 mg in patients with mixed dyslipidemia. METHODS: A total of 760 patients with TG 150 mg/dL, HDL-C <40 mg/dL (& …
This phase 3, multicenter, randomized, double-blind study evaluated the efficacy and safety of rosuvastatin 5 mg coadministered with feno
70 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page